12:00 AM
May 18, 2009
 |  BC Week In Review  |  Company News  |  Other News

Durect drug delivery news

Durect disclosed in its 1Q09 earnings that it reduced headcount across all functional areas by 41 (25%) in March to save cash. Durect is seeking a new partner for its Transdur-Sufentanil after Endo Pharmaceuticals...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >